Skip to main content
Karen Ferrante, MD, Oncology, East Greenwich, RI

KarenJeanFerranteMD

Oncology East Greenwich, RI

Physician

Dr. Ferrante is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Ferrante's full profile

Already have an account?

  • Office

    Adirondack Dr
    East Greenwich, RI 02818

Education & Training

  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1989 - 1991
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1988 - 1989
  • Georgetown University School of Medicine
    Georgetown University School of MedicineClass of 1988
  • Providence College
    Providence CollegeBS, Cum Laude, 1980

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1993 - 2019

Awards, Honors, & Recognition

  • Named Pharma Voice Top 100 Most Inspiring People 2012
  • People Leader Award Pfizer, 2006
  • Achievement Award Pfizer, 2005
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer  
    Montgomery B, Eisenberger MA, Rettig MB, Chu FM, Pili R, Stephenson J, Vogelzang NJ, Koletsky AJ, Nordquist LT, Edenfield WJ, Mamlouk K, Ferrante KJ, Taplin, ME, Clin. Cancer Res, 1/2/2015
  • A Phase 1 and Pharmacologic Study of the Matrix Metalloproteinase Inhibitor CP-471,358 in Patients with Advanced Solid Tumors  
    Planting A, van der Gaast A, Schoffski P, Bartkowski M, Verheij C, Noe D, Ferrante K, Verweij J, Cancer Chemotherapy and Pharmacology, 1/1/2005
  • A Phase 1 Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors  
    Moulder S, Mahany JJ, Lush R, Rocha-Lima C, Langevin M, Ferrante KJ, Bartkowski LM, Kajiji SM, Noe DA, Paillet S, Sullivan S, Clinical Cancer Research, 1/1/2004
  • Join now to see all

Abstracts/Posters

  • Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-re...
    Taplin ME, Antonarakis ES, Ferrante KJ, Horgan K, Blumenstein B, Saad F, Luo J, de Bono J, ASCO Annual Meeting, 1/1/2017
  • Galeterone in Treatment-naive Patients with Castration-resistant Prostate Cancer with C-terminal Androgen Receptor Loss: Results from ARMOR2.
    Taplin ME, Chu F, Cochran J, Ferrante K, Lipsitz D, Roberts J, Sartor O, Heath E, ASCO Annual Meeting, 1/1/2016
  • Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V...
    Antonarakis E, de Bono J, Ferrante K, Horgan K, Luo J, Saad F, Taplin ME, ASCO Annual Meeting, 1/1/2016
  • Join now to see all

Lectures

  • "Cancer management in the 90's, the latest trends" 
    Waltham, MA - 1/1/1995

Professional Memberships